| Literature DB >> 32942989 |
Alexandrine Ferry1, Frank Plaisant1, Christophe Ginevra2, Yann Dumont2, Jacqueline Grando2, Olivier Claris1,3, François Vandenesch2,4, Marine Butin5,6.
Abstract
BACKGROUND: Enterobacter cloacae species is responsible for nosocomial outbreaks in vulnerable patients in neonatal intensive care units (NICU). The environment can constitute the reservoir and source of infection in NICUs. Herein we report the impact of preventive measures implemented after an Enterobacter cloacae outbreak inside a NICU.Entities:
Keywords: Biocleaning; Cephalosporins; Enterobacter cloacae; NICU; Outbreak
Mesh:
Year: 2020 PMID: 32942989 PMCID: PMC7500001 DOI: 10.1186/s12879-020-05406-8
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1Number of Enterobacter cloacae positive samples (blood/CSF culture or stool culture) isolated each month in one NICU setting, between January 2012 and January 2018
Fig. 2Number of patients exposed to three antibiotic classes administered in the NICU setting, for 1000 patient-day, between 2012 and 2017. “Other beta-lactams” include amoxicillin, amoxicillin-clavulanic acid and penicillin G. “Carbapenems” include imipenem and meropenem
Characteristics of the 30 neonates infected with Enterobacter cloacae in one NICU setting between January 2012 and January 2018
| Basic data | |
| sex ratio (M/F) | 17/13 |
| gestational age of birth (weeks)a | 28.6 [24.3–41.1] |
| birth weight (g)a | 930 [515–3770] |
| intra-uterine growth retardation, no (%) | 10 (33.3%) |
| antenatal corticosteroids, no (%) | 26 (86.7%) |
| caesarean, no (%) | 25 (83.3%) |
| Apgar score (5 min)a | 9 [1–10] |
| surgery before sepsis, no (%) | 2 (6.7%) |
| | 1 (3.3%) |
| Sepsis data | |
| colonization with | 4 (13.3%) |
| age at the onset of sepsis (days)a | 7 [0–50] |
| fever, no (%) | 11 (36.7%) |
| respiratory signs, no (%) | 21 (70%) |
| hemodynamic signs, no (%) | 27 (90%) |
| gastrointestinal signs, no (%) | 15 (50%) |
| hyperglycaemia, no (%) | 4 (13.3%) |
| central venous line at onset, no (%) | 23 (76.7%) |
| CSF positive for | 2/18b (11%) |
| Evolution | |
| length of staya,d | 47 [10–185] |
| necrotizing enterocolitis, no (%) | 4 (13.3%) |
| death / death caused by sepsis, no (%) | 12 (40%)/ 10 (33.3%) |
| delay between onset of sepsis and death (days)a | 3 [0–26] |
| Management | |
| central venous line removal, no (%) | 7/23c (30.4%) |
| Antibiotics | |
| Carbapenem, no (%) | 24 (80%) |
| Cephalosporins, no (%) | 24 (80%) |
| Aminoglycosides, no (%) | 30 (100%) |
| Ciprofloxacin, no (%) | 5 (16.7%) |
| Piperacillin, no (%) | 1 (3.3%) |
| duration of antibiotic (days)a,d | 15 [10–34] |
aValues are median [extremes]
bA bacterial analysis of CSF (cerebrospinal fluid) was performed in only 18 of the 30 patients
cOnly 23 of the 30 patients patients had a central line at the onset of the sepsis
dData are presented for the 18 patients who survived
Fig. 3Phylogenetic tree based on whole genome sequencing comparison of six Enterobacter cloacae strains from the studied NICU (represented by red squares) with the 438 publicly available reference genomes of Enterobacter cloacae using popPUNK software